Aijun Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aijun Yin has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Zhaoyang Zhang
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, China; Shandong Key Laboratory of Reproductive Health and Birth Defects Prevention and Control, Qilu Hospital of Shandong University, Jinan, China
2 shared publicationsBeihua Kong
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China; Gynecologic Oncology Key Laboratory of Shandong Province, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China
1 shared publication- Beihua Kong
Department of Obstetrics and Gynecology, QiLu Hospital of ShanDong University, JiNan, China
1 shared publication Bingxin Zhang
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China
1 shared publication- Changbin Zhu
Amoy Diagnostics Co., Ltd, Xiamen, People’s Republic of China
1 shared publication Chen Zhao
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China; Gynecologic Oncology Key Laboratory of Shandong Province, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China
1 shared publication
Latest Publications
- 19 December 2025
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 234 (5) , 1416-1449
The prognostic and clinical significance of cervical stromal invasion in endometrial cancer: a multicenter retrospective study
- 19 December 2025
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 234 (5) , 1416-1449
The prognostic and clinical significance of cervical stromal invasion in endometrial cancer: a multicenter retrospective study
- Open Access
- 25 April 2025
- Published by Springer Nature in Diagnostic Pathology
- Vol. 20 (1) , 1-10
Molecular subtyping of endometrial cancer via a simplified one-step NGS classifier, ARID1A and ZFHX4 mutations help further subclassify CNL/MSI-H patients
Background: Molecular subtyping has changed the prognostic stratification and therapeutic guidance for patients with endometrial cancer (EC). However, simultaneous application of sanger sequencing and immunohistochemistry under ProMisE criteria may be time- and tissue-consuming. This study attempted to measure subtype-specific biomarkers by one-step next-generation sequencing (NGS) resulting in a shorter turnaround time and less requirement of tissue samples. Methods: FFPE samples from 233 EC patients were retrospectively collected. Overall survival (OS) information was available for 131 patients with a median follow-up of 66 months. Genomic DNA was extracted and subjected to a one-step NGS panel including TP53, POLE and MSI measurement. Further comprehensive genomic analyses were performed on DNA from MSI-H and copy number low (CNL) subtypes. Results: The molecular typing ratio of the 233 patients was 8.15% for POLE subtype, 18.88% for MSI-H subtype, 11.59% for copy number high (CNH) subtype and 61.37% for CNL subtype. The 10-year OS and disease-specific survival (DSS) rate was 100% in POLE subtype, while only 33.51% and 39.69% in CNH subtype. In patients with CNL and CNL/MSI-H subtypes, ARID1A and ZFHX4 mutations were significantly associated with worse prognosis respectively. Conclusion: This simplified one-step NGS panel can effectively subgroup EC patients into four prognostically different subtypes. New biomarkers are able to potentially refine the classification of patients with CNL/MSI-H subtypes into groups with distinct clinical outcomes.
- 25 April 2025
- Published by Springer Nature in Diagnostic Pathology
- Vol. 20 (1) , 1-10
Open AccessMolecular subtyping of endometrial cancer via a simplified one-step NGS classifier, ARID1A and ZFHX4 mutations help further subclassify CNL/MSI-H patients
Background: Molecular subtyping has changed the prognostic stratification and therapeutic guidance for patients with endometrial cancer (EC). However, simultaneous application of sanger sequencing and immunohistochemistry under ProMisE criteria may be time- and tissue-consuming. This study attempted to measure subtype-specific biomarkers by one-step next-generation sequencing (NGS) resulting in a shorter turnaround time and less requirement of tissue samples. Methods: FFPE samples from 233 EC patients were retrospectively collected. Overall survival (OS) information was available for 131 patients with a median follow-up of 66 months. Genomic DNA was extracted and subjected to a one-step NGS panel including TP53, POLE and MSI measurement. Further comprehensive genomic analyses were performed on DNA from MSI-H and copy number low (CNL) subtypes. Results: The molecular typing ratio of the 233 patients was 8.15% for POLE subtype, 18.88% for MSI-H subtype, 11.59% for copy number high (CNH) subtype and 61.37% for CNL subtype. The 10-year OS and disease-specific survival (DSS) rate was 100% in POLE subtype, while only 33.51% and 39.69% in CNH subtype. In patients with CNL and CNL/MSI-H subtypes, ARID1A and ZFHX4 mutations were significantly associated with worse prognosis respectively. Conclusion: This simplified one-step NGS panel can effectively subgroup EC patients into four prognostically different subtypes. New biomarkers are able to potentially refine the classification of patients with CNL/MSI-H subtypes into groups with distinct clinical outcomes.
- 27 January 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 218, 115258
The prognostic and clinical significance of substantial lymphovascular space invasion in early-stage endometrial carcinoma
- 27 January 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 218, 115258
The prognostic and clinical significance of substantial lymphovascular space invasion in early-stage endometrial carcinoma